



City Health Information

DETECTING AND TREATING DEPRESSION IN ADULTS

- Many patients with depression seek medical care for other concerns, but depression remains undiagnosed.
- Primary care physicians can effectively detect and manage depression.
- Routinely screen adults for depression using a simple 2-question tool (PHQ-2).
- Engage patients in treatment planning and provide pharmacotherapy when appropriate (see page 3).

INSIDE THIS ISSUE

INTRODUCTION

Groups at higher risk for depression (box)

BE AWARE OF SIGNS AND SYMPTOMS OF DEPRESSION

Selected conditions and behaviors associated with depression (box)

IDENTIFY DEPRESSION

Patient Health Questionnaire-2 (PHQ-2) (box)

Patient Health Questionnaire (PHQ-9) (box)

PHQ-9 scores translated into DSM-5 diagnoses and practice (box)

Screening for alcohol and drug use (box)

ASSESS AND MANAGE SUICIDE RISK

Suicide risk and protective factors (box)

Suicide risk assessment and intervention (box)

ENGAGE THE PATIENT IN TREATMENT PLANNING

What to tell patients about depression (box)

Engaging patients in treatment planning (box)

NONPHARMACOLOGIC APPROACHES

PHARMACOLOGIC THERAPY

First-line antidepressants for adults (table)

Antidepressant agents: dosing ranges and guidelines for major depressive disorder (table)

What to tell patients about pharmacotherapy for depression (box)

MONITOR RESPONSE AND ADJUST TREATMENT

PREVENT RELAPSE

SPECIAL CONSIDERATIONS

Collaborative care for depression (box)

When to involve a mental health specialist (box)

SUMMARY

How to detect and treat depression in primary care (box)

Reimbursement for depression-related services (box)

RESOURCES FOR PROVIDERS

RESOURCES FOR PATIENTS

REFERENCES

Depression is a major cause of morbidity and mortality that often goes untreated. Nearly 1 in 6 adults in the United States suffer from depression during their lifetimes.¹ Based on a population-based survey that included a clinical interview, only 55% of adults in New York City (NYC) with depression had ever been told by a provider that they have the illness and only 36% said they had recently been treated for depression.²

Certain groups, including people with certain medical conditions, people living in poverty, and postpartum women, are more at risk for depression (**Box 1**).³⁻⁸ In NYC, people living at the highest level of poverty are more likely to have suffered from depression than those at higher income levels (18% vs 11%).³ Estimates of the prevalence of depression range from 13% to 19% among postpartum women.⁴



Depression can be treated. Primary care is an ideal setting to identify and offer treatment for depression because most patients see a primary care physician (PCP), but don't access mental health services. In one national study, 78% of people with depression saw a PCP, while only 18% saw a mental health specialist.⁹ A review of older patients who committed suicide showed that 58% had visited their PCP within the previous month and 77% had done so within the previous year.¹⁰

Barriers to screening may include inadequate physician training in diagnosing and managing mental health conditions and inadequate health plans. But underdiagnosis deprives patients of access to effective treatment.

New national guidelines recommend asking adults, including pregnant women and postpartum women, about depression.¹¹ Screen for depression using a simple 2-question tool, the Patient Health Questionnaire-2 (PHQ-2), at least annually or when clinically indicated. Work with the patient to develop the treatment plan—which may include both nonpharmacologic and pharmacologic approaches.

BE AWARE OF SIGNS AND SYMPTOMS OF DEPRESSION

There is a bidirectional relationship between depression and many medical conditions (**Box 2**)¹²⁻¹⁸; the health behaviors and physiological changes associated with depression increase the risk for chronic medical disorders, and biological changes and complications associated with chronic medical disorders may precipitate depressive episodes.^{19,20}

When seeing a patient, especially patients with chronic or severe physical illnesses¹²:

- Be attentive to clues suggesting depression. These can include multiple (>5) medical visits per year, multiple unexplained symptoms, dampened affect, weight gain or loss, sleep disturbance, fatigue; complaints about memory/cognition, stress, or mood disturbance.
- Be aware that cultural experiences can affect patients' views of symptoms, diagnoses, and treatments.^{12,21}
- Use an interpreter or interpretation service to overcome linguistic barriers.^{12,21}

BOX 1. GROUPS AT HIGHER RISK FOR DEPRESSION³⁻⁸

- People living in poverty
- People in short-term financial distress
- Postpartum women
- People with chronic medical conditions and risk behaviors (**Box 2**)
- LGBT individuals
- People who have
 - o a family history of depression
 - o a history of neglect or exposure to trauma

IDENTIFY DEPRESSION

Routinely screen adults for depression¹¹ using the PHQ-2 (**Box 3**²²), at least annually or when clinically indicated. Explain that routine screening is now recommended because depression is very common and effective treatment is available, and offer to perform the screen.

If the patient answers "yes" to either item on the PHQ-2, evaluate further with the Patient Health Questionnaire (PHQ-9) (**Boxes 4**²³ and **6**^{12,24}). The PHQ-9 is available in multiple languages (**Resources**).

When reviewing the responses to the PHQ-9 with the patient, ask about

- Other symptoms and history, including history of and treatment for depression and suicide attempts.
- Other mental health conditions (eg, anxiety).
- Medical conditions and medications that can cause or worsen depression.
- Alcohol and drug use (**Box 5**^{25,26}).
- Family history of depression (including suicide attempts and treatment).

If the patient gives a positive response to question 9 of the PHQ-9 or if you suspect suicidal thinking, assess and manage suicide risk (see page 5).

BOX 2. SELECTED CONDITIONS AND BEHAVIORS ASSOCIATED WITH DEPRESSION¹²⁻¹⁸

- | | |
|-------------------------------------|-------------------------|
| • Substance use (including alcohol) | • Smoking |
| • Anxiety | • COPD |
| • Diabetes | • HIV |
| • Rheumatoid arthritis | • Asthma |
| • Hypertension | • Obesity |
| • Cardiovascular disease | • Stroke |
| • Coronary artery disease | • Alzheimer's disease |
| • Cancer | • Myocardial infarction |
| • Sleep disorders | • PTSD |
| • Chronic pain | • Eating disorder |

BOX 3. PATIENT HEALTH QUESTIONNAIRE-2 (PHQ-2)²²

Over the past 2 weeks, have you been bothered by:

1. Little interest or pleasure in doing things?
2. Feeling down, depressed, or hopeless?

If "yes" to either question, screen with the Patient Health Questionnaire (PHQ-9) (see page 3).

BOX 4. PATIENT HEALTH QUESTIONNAIRE (PHQ-9)²³

Over the last 2 weeks, how often have you been bothered by any of the following problems? (use “✓” to indicate your answer)

	Not at all	Several days	More than half the days	Nearly every day
1. Little interest or pleasure in doing things	0	1	2	3
2. Feeling down, depressed, or hopeless	0	1	2	3
3. Trouble falling or staying asleep, or sleeping too much	0	1	2	3
4. Feeling tired or having little energy	0	1	2	3
5. Poor appetite or overeating	0	1	2	3
6. Feeling bad about yourself — or that you are a failure or have let yourself or your family down	0	1	2	3
7. Trouble concentrating on things, such as reading the newspaper or watching television	0	1	2	3
8. Moving or speaking so slowly that other people could have noticed. Or the opposite — being so fidgety or restless that you have been moving around a lot more than usual	0	1	2	3
9. Thoughts that you would be better off dead, or of hurting yourself in some way	0	1	2	3
	add columns: <input type="text"/> + <input type="text"/>		+ <input type="text"/>	
(Health care professional: For interpretation of TOTAL, please refer to Box 6 on page 4.)	TOTAL: <input type="text"/>			
10. If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?	Not difficult at all _____		Somewhat difficult _____	
	Very difficult _____		Extremely difficult _____	

Source: www.integration.samhsa.gov/images/res/PHQ%20-%20Questions.pdf.

Note: For patients who give a positive response to question 9, assess and manage suicide risk (see page 5).

BOX 5. SCREENING FOR ALCOHOL AND DRUG USE^{25,26}

Alcohol use²⁵

1. Prescreen: “Do you sometimes drink alcoholic beverages?”
If yes: “How many times in the past year have you had X or more drinks in a day?” (X=5 for men and <65 years, 4 for all women and for men aged 65+)
2. If the response is ≥ 1 , screen with AUDIT. See *City Health Information: Brief Intervention for Excessive Drinking* for more information.

Drug use²⁶

1. Ask “How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?”
2. If ≥ 1 , screen with a clinical tool such as NIDA-ASSIST. See *City Health Information: Improving the Health of People Who Use Drugs* for more information.

If a patient has co-occurring depression and substance use disorder or other mental health condition (eg, anxiety), refer to or co-manage with a mental health provider.¹²

ASSESS AND MANAGE SUICIDE RISK

Depression is a risk factor for suicide (**Box 7**)²⁷; the prevalence of suicide ideation among people who suffered from major depression in the past year is 26%, as opposed to 2% among adults who did not suffer from major depression in the past year.²⁸ Knowing how to detect suicidal risk and when and how to intervene can be life-saving. Asking a patient about suicidal thoughts or plans does not initiate such ideas or foster action.

A positive response to item 9 on the PHQ-9 is associated with a higher risk of suicide attempts.²⁹ Conduct a suicide assessment (**Box 9**)^{30,31} on any patient who answers “yes” to question 9, or whom you judge to be at possible risk, and intervene according to responses. See *Intermountain Healthcare. Management of Depression—2015 update* and *Suicide Risk Assessment Tools (Resources)* for detailed guidance.

ENGAGE THE PATIENT IN TREATMENT PLANNING

Successful care of depression requires active engagement of patients and their families, beginning at diagnosis^{12,19,32-35} (**Boxes 8**)^{30,31} and **10**)^{12,35}. Collaborate with patients in developing

(Continued on page 5)

BOX 6. PHQ-9 SCORES TRANSLATED INTO DSM-5 DIAGNOSES AND PRACTICE^{12a,24}

PHQ-9 Symptoms and Impairment	PHQ-9 Scores	Intensity	Initial Management	Next Steps
<ul style="list-style-type: none"> • 1-4 symptoms • Minimal functional impairment 	5-9	Subclinical*	<ul style="list-style-type: none"> • Instruct the patient to call if he or she feels worse • Prescribe physical activity • Educate patient to schedule daily pleasurable activities 	If no improvement in 1 month, consider referral to behavioral health for evaluation
<ul style="list-style-type: none"> • 2 symptoms • Score 2+ on Question 1 or 2 • Functional impairment 	10-14	Mild Major Depression	All actions for Subclinical Depression, plus <ul style="list-style-type: none"> • Psychotherapy, pharmacotherapy, or both 	Consider weekly contact initially to ensure adequate engagement, then at least monthly
<ul style="list-style-type: none"> • ≥3 symptoms • Score 2+ on Question 1 or 2 • Functional impairment 	15-19	Moderate Major Depression	All actions for Mild Major Depression	Initially consider weekly contact to ensure adequate engagement, then minimum every 2-4 weeks (unless in mental health treatment elsewhere)
<ul style="list-style-type: none"> • ≥4 symptoms • Score 2+ on Question 1 or 2 • Marked functional impairment • Motor agitation 	≥20	Severe Major Depression	All actions for Mild Major Depression: pharmacotherapy necessary; psychotherapy when patient is able to participate	Weekly contact until less severe (unless in mental health treatment elsewhere)

* Consider for persistent depressive disorder. Persistent depressive disorder is defined as low-level depression most of the day for more days than not for at least 2 years. Must include presence of at least 2 of the listed DSM-5 criteria affecting appetite, sleep, fatigue, self-esteem, concentration/decision-making, or hopelessness.²⁴ Initiate pharmacotherapy or refer to mental health specialty clinician for evaluation, or both.

Note: This table is designed to translate the PHQ-9 scores into DSM-5 categories; it does not directly correspond to the PHQ-9 Scoring Guide at www.integration.samhsa.gov/images/res/PHQ%20-%2020Questions.pdf.

Adapted from Mitchell J, Trangle M, Degnan B, et al; Institute for Clinical Systems Improvement. *Adult Depression in Primary Care*. Updated September 2013. Bloomington, MN: Institute for Clinical Systems Improvement; 2013.

BOX 7. SUICIDE RISK AND PROTECTIVE FACTORS²⁷**Risk Factors**

- Prior suicide attempts or self-injurious behavior
- Family history of suicide, suicide attempts, or psychiatric diagnoses, especially those requiring hospitalization
- Current/past psychiatric disorders, especially depression, bipolar disorder, psychotic disorders, alcohol/substance abuse, traumatic brain injury, posttraumatic stress disorder, personality disorders (co-occurring disorders and recent onset of illness increase risk)
- Inability to feel pleasure, impulsivity, command hallucinations, intoxication
- Events leading to humiliation, shame, or despair (eg, loss of relationship, health, or financial status—real or anticipated)
- Recent loss through death, divorce, or separation¹²
- Chronic medical illness (**Box 2**)
- Past or current abuse or neglect

Protective Factors

- Internal: ability to cope with stress; religious beliefs; frustration tolerance
- External: responsibility to children or pets; positive therapeutic relationships; social supports

BOX 8. WHAT TO TELL PATIENTS ABOUT DEPRESSION^{30,31}

- Depression is a common medical illness.
- Don't feel ashamed or embarrassed about depression.
- Treating depression works for many patients—it may take up to several months to a year.
- Treatment for depression may improve your overall health.
- The aim of treatment is remission—that means being mostly free of symptoms.
- You and I will decide together what treatment to try.
- Relapse is common; stick with the treatment plan even after you feel better. Treatment involves staying well, not just getting well.
- Support from family and friends can help you follow the treatment plan and feel better.
- Let me know right away if you begin to feel worse, or feel that you want to hurt yourself, especially if the thoughts are frequent or more intense.
- If you are in crisis and need immediate help, call 800-273-TALK (8255) or 800-LIFENET (543-3638).
- If your life or someone else's is in immediate danger, call 911.

BOX 9. SUICIDE RISK ASSESSMENT AND INTERVENTION^{30,31}

If a patient responds positively to item 9 on the PHQ-9 or you suspect the patient has suicidal thoughts, screen for suicide risk using the Columbia-Suicide Severity Rating Scale (C-SSRS) Quick Screen.

Questions	Answers	Risk Level	Actions based on positive responses (respond based on highest level of risk)
1. Have you wished you were dead or wished you could go to sleep and not wake up? 2. Have you actually had any thoughts of killing yourself?	Yes to 1 and no to 2	Low	<ul style="list-style-type: none"> Consider referral to mental health or behavioral health provider Consider patient education (see page 3 and Resources for Patients) Ask question 6 (response may increase risk category)
If No to 1 and Yes to 2 or Yes to both, ask 3-6			
3. Have you been thinking about how you might want to kill yourself?	Yes	Moderate	<ul style="list-style-type: none"> Access risk factors and facilitate evaluation for inpatient admission, or complete safety plan with follow-up within 24-48 hours Educate patient
4. Have you had these thoughts and had some intention of acting on them? 5. Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?	Yes to 4 and/or 5	High	<ul style="list-style-type: none"> Facilitate immediate evaluation by psychiatrist or psychiatric nurse practitioner Educate patient
6. Have you ever done anything, started to do anything, or prepared to do anything to end your life?	If in the past 4 weeks	High	<ul style="list-style-type: none"> Facilitate immediate evaluation for inpatient care Educate patient
	If 1-12 months ago	Moderate	<ul style="list-style-type: none"> Assess risk factors and refer to mental health or behavioral health provider and educate patient, emphasizing importance of reporting suicidal thinking
	If ≥1 year ago	Low	<ul style="list-style-type: none"> Consider referral to mental or behavioral health provider and consider patient education

Adapted from Intermountain Health Care. Management of Depression—2015 Update.
<https://intermountainhealthcare.org/ext/Dcmnt?ncid=51061767>.

BOX 10. ENGAGING PATIENTS IN TREATMENT PLANNING^{12,35}

- Involve patients in deciding which form of treatment, ie, psychotherapy, pharmacotherapy, or both, to pursue.¹²
- Suggest learning and using self-management skills such as journal writing and self-monitoring.¹²
- Encourage use of support networks of family and friends for crisis intervention and relapse prevention.³⁵
- Encourage family or friends to attend appointments when appropriate.¹²
- Schedule follow-up appointments and phone calls for the first 12 months of care.¹²
- Establish a way to reach out if the patient drops out of care.¹²

(Continued from page 3)

or modifying the treatment plan^{12,35} and educate them about diagnosis, prognosis, and treatment options. Explain costs, duration, side effects, and expected benefits of any medication. Also, determine whether psychotherapy is available and whether the patient prefers it.¹²

NONPHARMACOLOGIC APPROACHES

Nonpharmacologic therapies for depression include self-management strategies and psychotherapy.

Self-management strategies

Physical activity³⁶: Strongly recommend 30 minutes of moderate-intensity aerobic physical activity, 3 to 5 days a week,¹² and follow up at each visit. Examples of moderate-intensity physical activity include walking briskly (3 miles per hour or faster, but not race-walking), water aerobics, bicycling, tennis (doubles), ballroom dancing, and gardening.³⁷ See **Resources for Patients** for information on exercise programs.

Behavioral changes¹²: While patients with depression struggle with an inability to feel pleasure, encourage those with

mild to moderate depression to schedule daily activities such as outings or getting together with friends. This approach (behavioral activation) can help reduce depressive symptoms,^{12,38,39} and for some patients the effect is comparable to pharmacotherapy after 4 months of treatment.⁴⁰

Healthy sleep and nutrition: Recommend that patients get enough sleep on a regular basis, eat a healthy diet, and avoid alcohol to help reduce symptoms of depression.⁶

Self-management documentation: Self-monitoring such as journal-writing can improve outcomes.¹² Encourage patients to share their self-management documentation with you to maintain engagement.

Psychotherapy¹²

Several psychotherapy modalities have proven benefits in treating depression:

- Cognitive behavioral therapy concentrates on identifying negative thought patterns and replacing them with positive thought patterns and rewarding activities.
- Interpersonal psychotherapy focuses on current problems and relationships.
- Psychodynamic psychotherapy/psychoanalysis is based on psychoanalytic theory and methods.⁴¹ Treatment can be short- or long-term.¹²
- Problem-solving treatment teaches adaptive problem-solving attitudes and skills.⁴²

PHARMACOLOGIC THERAPY

Several classes of medication are effective in treating depression^{35,43-45} (**Table 1**^{12,30,46-61}). In general, it is best to select initial treatment based on the patient's symptoms and the medication's side-effect profile (eg, sedating antidepressant for someone with insomnia). Also consider the patient's history of response to antidepressant medications, medication tolerability, cost, and medication interactions (see **Resources for Providers—Pharmacotherapy**)^{35,43,45,62} If prescribing pharmacotherapy, remember that effectiveness of the trial depends on duration, adherence, and dosage³⁵ (**Table 2**^{30,46-60}) and let the patient know what to expect when beginning the trial, including discussing potential side effects (**Box 11**^{12,46-60}).

MONITOR RESPONSE AND ADJUST TREATMENT

Establish and maintain follow-up office, phone, or other contact (see **Box 6**) to monitor and reassure the patient.

The goal of treatment is remission, or a score of <5 on the PHQ-9.¹² Full remission is defined as a 2-month period without major depressive signs or symptoms.¹² At each follow-up visit, use the PHQ-9 to assess response to treatment. To save time, the patient can complete the PHQ-9 before the visit. See **Resources for Providers—Pharmacotherapy** for guidance on switching medications.

BOX 11. WHAT TO TELL PATIENTS ABOUT PHARMACOTHERAPY FOR DEPRESSION^{12,46-60}

- You may start to feel better after 4-8 weeks, but it usually takes 6-12 months to feel the full benefits.
- You may feel side effects before your symptoms improve. Expect some discomfort before you feel the benefit of the medicine.
- Some side effects may go away with time and some can be managed by changing the dosing or schedule.
- We may have to adjust the dosage or try different medications to find the treatment that will give you the best response with the fewest side effects. It's important that you don't get discouraged.
- Take the medication as prescribed, even after you feel better, to reduce the chance of relapse.
- Do not stop taking your medicine suddenly. We need to reduce the dosage gradually in order to avoid or minimize withdrawal symptoms, especially if you've been taking the medication for 6 weeks or more.

Be aware that improvement with psychotherapy may be slower than with pharmacotherapy. It may take 8 to 10 weeks before response can be evaluated.¹² If improvement is not adequate after initial treatment and the patient has been seen at least once a week, consider switching to another psychotherapeutic approach and/or adding pharmacotherapy.¹²

PREVENT RELAPSE

To prevent relapse, continue pharmacotherapy after remission is achieved, based on the patient's history of major depression.¹²

- First episode: continue for 4-9 months.
- Second episode: Continue for 2 years and discuss with the patient the possibility of withdrawing gradually.
- Persistent depressive disorder: Continue medication treatment indefinitely.

See **Resources for Providers—Depression Management** for further guidance. (Continued on page 9)

COLLABORATIVE CARE FOR DEPRESSION

In the collaborative care model, primary care providers, care managers, and mental health providers work together to help patients with depression.

Collaborative care for depression

- Improves depression symptoms, adherence to treatment, and remission and recovery^{63,64}
- Improves treatment engagement among underserved racial and ethnic groups⁶⁵
- Significantly improves co-morbid depression and diabetes measures^{66,67}

The best models involve care coordination and case management; regular/proactive monitoring and treatment; and regular psychiatric reviews and consultation for patients who do not show clinical improvement.⁶⁸

TABLE 1. FIRST-LINE ANTIDEPRESSANTS FOR ADULTS^{12,30,46-61}

Class/Drug	Clinical Considerations (see product prescribing information for details)
Selective Serotonin Reuptake Inhibitors (SSRIs)	
Citalopram (Celexa®) ^{*,a}	<ul style="list-style-type: none"> Common side effects: headache, somnolence, insomnia, nausea, diarrhea, dry mouth, fatigue, sexual dysfunction, nervousness, agitation, restlessness, weight gain Taper to reduce risk of discontinuation syndrome, particularly with paroxetine and sertraline (not necessary with fluoxetine) Potentially lethal interaction with monoamine oxidase inhibitors (MAOIs). If MAOI treatment is considered, consult a drug information reference or psychiatrist for dosing, wash-out period, monitoring, and drug-drug and drug-food interactions
Escitalopram (Lexapro®)	
Fluoxetine (Prozac®)	
Paroxetine (Pexeva®, Paxil CR®)	
Sertraline (Zoloft®)	
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)	
Duloxetine (Cymbalta®) ^b	<ul style="list-style-type: none"> Common side effects: nausea, dry mouth, headache, constipation, diarrhea, dizziness, drowsiness, insomnia, activation, dose-related increases in blood pressure, sexual dysfunction, weight gain Increased risk of liver damage for patients with substantial alcohol use or preexisting liver disease Do not use with an MAOI or within 14 days of stopping an MAOI. Allow 7 days after stopping the SNRI before starting an MAOI Monitor blood pressure during dose titration and throughout treatment Taper to reduce risk of discontinuation syndrome May increase risk of bleeding events
Levomilnacipran (Fetzima®) ^c	
Venlafaxine (Effexor XR®)	
Desvenlafaxine (Pristiq®) Generic not available	
Other Agents	
Bupropion HCl (Wellbutrin SR® or XL®), ^c dopamine-norepinephrine reuptake inhibitor	<ul style="list-style-type: none"> Common side effects: agitation, dry mouth, constipation, headache/migraine, nausea/vomiting, dizziness, excessive sweating, tremor, insomnia, blurred vision, tachycardia, confusion, rash, hostility, cardiac arrhythmias, and auditory disturbance May improve sexual desire No weight gain and may help with weight loss Useful as a smoking cessation agent
Mirtazapine (Remeron®), norepinephrine-serotonin release enhancer	<ul style="list-style-type: none"> Common side effects: somnolence, weight gain, dizziness, dry mouth, increased appetite, constipation, weight gain Minimal sexual dysfunction Do not use with an MAOI or within 14 days of stopping an MAOI
Vilazodone (Viibryd®), SSRI, 5HT1A receptor partial agonist Generic not available	<ul style="list-style-type: none"> Common side effects: diarrhea, nausea, vomiting, insomnia May increase risk of bleeding events Taper to reduce risk of discontinuation syndrome Do not use with an MAOI or within 14 days of stopping an MAOI
Vortioxetine (Brintellix®), SSRI, 5HT3 receptor antagonist, 5HT1A agonist Generic not available	<ul style="list-style-type: none"> Common side effects: nausea, constipation, vomiting Generally not used first-line May increase risk of bleeding events May be decreased to 5 mg/day if patients are intolerant to higher doses May be discontinued abruptly if needed; taper recommended Do not use with an MAOI or within 14 days of stopping an MAOI

CR, controlled release; XR, extended release; SR, sustained release; XL, extended release.

* Use of brand names is for informational purposes only and does not imply endorsement by the New York City Department of Health and Mental Hygiene.

^a Avoid doses greater than 40 mg daily due to dose-dependent increased risk for QTc prolongation. Obtain ECG at baseline in patients with history of CHF, bradyarrhythmias, or concurrent administration of other QTc-prolonging medications. Check potassium and magnesium levels at baseline for patients at risk of electrolyte abnormalities.

^b Hepatic function test at baseline.

^c Bupropion IR is not recommended due to seizure risk and poor tolerability. Bupropion is contraindicated in patients with a history of seizure disorder or eating disorder (IR is highest risk).

Note: Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants.

TABLE 2. ANTIDEPRESSANT AGENTS: DOSING RANGES AND GUIDELINES FOR MAJOR DEPRESSIVE DISORDER^{30,46-60}

Agent	Dose (once daily unless noted)			Comments
	Start	Maintenance	Maximum	
Bupropion HCl (Wellbutrin SR [®])	100 mg (not at nighttime)	100 mg, 2-3x/day	150 mg, 3x/day	Increase dose gradually to reduce seizure risk Caution with co-morbid anxiety
Bupropion HCl (Wellbutrin XL [®])	150 mg (morning)	150-300 mg	450 mg	Increase dose gradually to reduce seizure risk Caution with co-morbid anxiety
Citalopram (Celexa [®]) ^a	10 mg/day for first 7 days	20-40 mg	40 mg	Dose 10 mg/day for 7 days, then increase to 20 mg Dose-dependent increased risk for QTc prolongation
Duloxetine (Cymbalta [®])	30-60 mg	30-60 mg	120 mg	
Escitalopram (Lexapro [®])	10 mg	10-20 mg	20 mg	Allow at least ≥3 weeks at 10 mg/day before increasing
Fluoxetine (Prozac [®])	10 mg/day for first 7 days (morning)	20-60 mg 1x/day (morning) or 2x/day (morning; noon)	80 mg	Dose 10 mg/day for first 7 days, then increase to 20 mg (morning) Also in once-weekly 90-mg capsule
Levomilnacipran (Fetzima [®])	20 mg for first 2 days	40-120 mg	120 mg	Dose 20 mg for 2 days, then increase to 40 mg daily May increase by 40 mg every 2 days
Mirtazapine (Remeron [®])	15 mg	15-45 mg, 1x/day	45 mg	Take at bedtime Titrate to effect and tolerability in intervals of 1-2 weeks Minimal sedating effect beyond 15 mg
Paroxetine (Paxil [®])	20 mg (IR) OR 25 mg (CR)	20-50 mg once daily (IR) OR 25-62.5 mg once daily (CR)	50 mg (IR) OR 62.5 mg (CR)	IR: 10 mg/day increments, intervals at least 1 week CR: 12.5-mg/day increments, 1- to 2-week intervals
Desvenlafaxine (Pristiq [®])	50 mg, 1x/day	50 mg once daily	50 mg, 1x/day	Generic not available. Taper down with 25-mg dose when discontinuing
Sertraline (Zoloft [®])	25 mg/day for first 7 days	50-200 mg once daily	200 mg, 1x/day	Dose at 25 mg/day for 7 days, then increase to 50 mg/day
Venlafaxine (Effexor XR [®])	37.5 mg/day for first 7 days	75-225 mg once daily	225 mg, 1x/day	Dose 37.5 mg/day for first 7 days, then increase to 75 mg, 1x/day Take with food. Taper down 75 mg/week to discontinue
Vilazodone (Viibryd [®])	10 mg, 1x/day	40 mg, 1x/day	40 mg, 1x/day	Generic not available
Vortioxetine (Brintellix [®])	10 mg, 1x/day	10-20 mg once daily	20 mg, 1x/day	Generic not available In patients taking 15-20 mg/day, decrease to 10 mg/day for 1 week, then discontinue

SR, sustained release; XL, extended release; CR, controlled release; IR, immediate release; XR, extended release.

^a Obtain ECG at baseline in patients with history of CHF, bradyarrhythmias, or concurrent administration of other QTc-prolonging medications. Check potassium and magnesium levels at baseline for patients at risk of electrolyte abnormalities.

(Continued from page 6)

SPECIAL CONSIDERATIONS

Pregnancy and breastfeeding

- Depression during or after pregnancy is very common.
- In addition to common signs and symptoms of depression, the mother may
 - fear that something bad will happen to the baby,
 - have thoughts that she may harm the baby herself,
 - have trouble feeling connected with the baby.
- Postpartum depression can impact maternal care-taking behaviors, as well as the behavior, cognitive development, and physical health of the child.⁴
- If a patient is pregnant, planning to breastfeed, or is breastfeeding, stay current with research on risks and benefits of psychotropic medications or consult with an expert.⁶⁹
- Help pregnant and breastfeeding patients assess the negative effects of depression on themselves and their families, as well as the risks and benefits of pharmacotherapy and other treatment options,¹² or refer to a specialized provider.

Older adults

- Older adults may be taking several medications, so interactions are an important consideration.
- Be aware that older patients may have to be treated longer to achieve remission.¹²

Children, adolescents, and adults aged 18 to 24

- Antidepressants carry an FDA-issued black box warning about increased risks of suicidal thinking and behaviors during initial treatment (generally first 1 or 2 months) of patients aged 24 and younger.⁷⁰
- If antidepressant medication is indicated in a young patient, start with a low dose and increase slowly, carefully monitoring the patient for new or worsening suicidal thoughts or behaviors.^{70,71}

Some patients (**Box 12¹²**) may benefit from a referral to a mental health clinician who can consider additional strategies, such as psychotherapy, auxiliary medication, hospitalization, electroconvulsive treatment (ECT), or light therapy. Consider co-managing with the specialist if possible.

BOX 12. WHEN TO INVOLVE A MENTAL HEALTH SPECIALIST¹²

Refer to or co-manage with a mental health specialty clinician when needed¹²:

- High suicide risk
- Patient preference
- Signs and symptoms continue to interfere with work, school, family care, or other basic needs and relationships
- Other psychiatric disorders such as bipolar or substance abuse
- Complex psychosocial needs

SUMMARY

Depression is a common and debilitating illness that can affect a patient's overall health. Be alert to risk factors for depression and use standardized tools to screen and diagnose. Engage the patient in developing the treatment plan, which may include a variety of modalities, and closely monitor response. ♦

HOW TO DETECT AND TREAT DEPRESSION IN PRIMARY CARE

- Screen with the PHQ-2.
- If the PHQ-2 is positive, assess further with the PHQ-9.
- Engage the patient in treatment planning.
- Closely monitor progress.
- Refer to or co-manage with a mental health specialist when necessary.

REIMBURSEMENT FOR DEPRESSION-RELATED SERVICES

Depression (ICD-10: Z13.89)	Codes	Comments
Medicare	HCPCS: G0444	Annual depression screening, 15 min
Medicaid Fee For Service	HCPCS: G8431	Documented positive screen and follow-up plan
Medicaid Managed Care	HCPCS: G8510	Documented negative screen; no follow-up plan required
Aetna Commercial	HCPCS: G8510	Documented negative screen; no follow-up plan required
Emblem Commercial	CPT: 96127	Annual depression screening, 15 min, patients aged ≥12 years
Postpartum Depression Screening ^a (ICD-10: O90.6)		
Medicaid Fee for Service ^b	HCPCS: G8431 (HD)	Documented positive screen and follow-up plan
Medicaid Managed Care ^c	HCPCS: G8510 (HD)	Documented negative screen; no follow-up plan required
Prenatal Depression Screening		
	HCPCS: H1000, H1005	

^a Postpartum maternal depression screening with a validated screening tool may be reimbursed up to 3 times in the first year of the infant's life. If screening is performed on the same day as the infant's primary care visit (E&M) by the infant's health care provider, one claim can be submitted for both services using the appropriate maternal "G" series code under the infant's Medicaid identification number. Alternatively, providers, including pediatricians, may bill this service separately under the mother's Medicaid identification number.

^b Effective September 1, 2016.

^c Effective November 1, 2016.

RESOURCES FOR PROVIDERS

Depression Management

- American Psychiatric Association. Treating Major Depressive Disorder: A Quick Reference Guide: psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd-guide.pdf
- Institute for Clinical Systems Improvement. Depression, Adult in Primary Care Guideline: www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_behavioral_health_guidelines/depression/
- Intermountain Health Care. Management of Depression—2015 Update: <https://intermountainhealthcare.org/ext/Dcmnt?ncid=51061767>

Depression Screening Tool

- Patient Health Questionnaire (PHQ-9): <http://www.phqscreeners.com/select-screener/36>

Perinatal Depression Guidelines

- Nassau County Best Practices Task Force: <http://ny2aap.org/pdf/NCPerinatalResourceGuideDec11.pdf>

Suicide Risk Assessment Tools and Other Materials

- Western Interstate Commission and Suicide Prevention Resource Center. Suicide Prevention Toolkit for Rural Primary Care Practices: www.sprc.org/sites/sprc.org/files/pctoolkit.pdf
- Intermountain Healthcare. Suicide Prevention: <https://intermountainhealthcare.org/ext/Dcmnt?ncid=526742474>

Pharmacotherapy Resources

- Interactions Checkers
 - The Physician's Desk Reference: <http://www.pdr.net>
 - Epocrates: <https://online.epocrates.com/interaction-check> (registration required)
- Choosing Antidepressants for Adults: <http://effectivehealthcare.ahrq.gov/repFiles/AntidepressantsClinicianGuide.pdf>
- Switching Medications
 - Health Alliance: https://www.healthalliance.org/media/Generics_antidepressants_comparison_chart.pdf (see page 2)
 - Switching Antidepressants: <http://wiki.psychiatrienet.nl/index.php/SwitchAntidepressants>

Mental Health Referrals

- LIFENET (24 hours a day/7 days a week)
 - In English: 800-LIFENET (800-543-3638)
 - In Spanish: 800-AYUDESE (877-298-3373)
 - In Korean and Chinese (Mandarin and Cantonese dialects): 800-ASIAN LIFENET (877-990-8585)
 - For other languages, call 800-LIFENET or 311 and ask for an interpreter.
 - For TTY (hard of hearing), call 212-982-5284 www1.nyc.gov/site/doh/health/health-topics/crisis-emergency-services-lifenet.page
- Anxiety and Depression Association of America: treatment.adaa.org

RESOURCES FOR PATIENTS

Patient Education Materials

- New York City Department of Health and Mental Hygiene
 - Common Symptoms of Depression Fact Sheet: www1.nyc.gov/assets/doh/downloads/pdf/csi/depressionkit-pt-symptoms-fact.pdf
 - *Health Bulletin #34, Feeling Better: Depression*: www1.nyc.gov/assets/doh/downloads/pdf/public/dohmhnews10-04.pdf
- Agency for Health Care Research and Quality. Mental Health: www.ahrq.gov/patients-consumers/treatmentoptions/consumer-mental-health.html
Brochures on treatment choices, and pharmacotherapy and its side effects
- National Institute of Mental Health. Depression: www.nimh.nih.gov/health/topics/depression/index.shtml
- National Alliance on Mental Illness. Depression: www.nami.org/Learn-More/Mental-Health-Conditions/Depression
- American Psychiatric Association. Help With Depression: www.psychiatry.org/patients-families/depression

Organizations and Support Groups

- Depression and Bipolar Support Alliance: www.dbsalliance.org
Education, wellness, and peer support services to patients, family members, and clinicians
- Mood Disorders Support Group New York: www.mdsg.org
Free, peer-run support groups in Manhattan
- Mental Health America: www.mentalhealthamerica.net/conditions/depression
- Suicide Prevention Resource Center: www.sprc.org/
- National Alliance on Mental Illness-New York: www.namincmetro.org/

Crisis Hotlines

- LIFENET (24 hours a day/7 days a week)
 - In English: 800-LIFENET (800-543-3638)
 - In Spanish: 800-AYUDESE (877-298-3373)
 - In Korean and Chinese (Mandarin and Cantonese dialects): 800-ASIAN LIFENET (877-990-8585)
 - For other languages, call 800-LIFENET or 311 and ask for an interpreter.
 - For TTY (hard of hearing), call 212-982-5284 www1.nyc.gov/site/doh/health/health-topics/crisis-emergency-services-lifenet.page
- National Suicide Prevention Lifeline (24 hours a day/7 days a week): 800-273-TALK (800-273-8255)

Physical Activity

- NYC Health Department. Physical Activity: www1.nyc.gov/site/doh/health/health-topics/physical-activity.page
 - Make NYC Your Gym
 - Bicycling in New York City
- New York City Office of the Mayor. Shape Up NYC: www1.nyc.gov/nyc-resources/service/2441/shape-up-nyc
Find a free fitness class

Postpartum Depression

- NYC Health Department: www1.nyc.gov/site/doh/health/health-topics/post-partum-depression.page
- Medline Plus (in 14 languages): www.nlm.nih.gov/medlineplus/languages/postpartumdepression.html

Depression in Older Adults

- NYC Department for the Aging: nyc.gov/html/dfta/html/health/mental.shtml

REFERENCES

- Reeves WC, Strine TW, Pratt LA, et al. Mental illness surveillance among adults in the United States. *MMWR Morb Mortal Wkly Rep*. 2011;60(03):1-32. www.cdc.gov/mmwr/preview/mmwrhtml/su6003a1.htm. Accessed September 22, 2015.
- Gwynn RC, McQuiston HL, McVeigh KH, Garg RK, Frieden TR, Thorpe LE. Prevalence, diagnosis, and treatment of depression and generalized anxiety disorder in a diverse urban community. *Psychiatr Serv*. 2008;59(6):641-647.
- New York City Department of Health and Mental Hygiene. EpiQuery. New York City Community Health Survey, 2013. a816-healthpsi.nyc.gov/epiquery/CHS/CHSXIndex.html. Accessed September 30, 2015.
- O'Hara MW, McCabe JE. Postpartum depression: current status & future directions. *Annu Rev Clin Psychol*. 2013;9:379-407.
- Center for Excellence for Transgender Health. *Primary Care Protocol for Transgender Patient Care*. April 2011. Transgender Health Program. transhealth.ucsf.edu/trans?page=protocol-00-00. Accessed October 8, 2015.
- American Psychiatric Association. What is depression? <http://www.psychiatry.org/patients-families/depression/what-is-depression>. Accessed March 1, 2016.
- Lorant V, Croux C, Weich S, Deliège D, Mackenbach J, Anseau M. Depression and socio-economic risk factors: 7-year longitudinal population study. *Br J Psychiatry*. 2007;190:293-298.
- Mayer KH, Bradford JB, Makadon HJ, Stall R, Goldhammer H, Landers S. Sexual and gender minority health: what we know and what needs to be done. *Am J Public Health*. 2008;98(6):989-995.
- Young AS, Klap R, Sherbourne CD, Wells KB. The quality of care for depressive and anxiety disorders in the United States. *Arch Gen Psychiatry*. 2001;58(1):55-61.
- Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide: a review of the evidence. *Am J Psychiatry*. 2002;159(6):909-916.
- Siu AL, US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, et al. Screening for depression in adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2016;316(4):380-387.
- Trangle M, Gursky J, Haight R, et al; Institute for Clinical Systems Improvement. *Adult Depression in Primary Care*. Updated March 2016. www.icsi.org/_asset/fnhdm3/Depr.pdf. Accessed April 5, 2016.
- Mitchell J, Trangle M, Degnan B, et al; Institute for Clinical Systems Improvement. *Adult Depression in Primary Care*. Updated September 2013. Bloomington, MN: Institute for Clinical Systems Improvement; 2013.
- Kessler RC. The costs of depression. *Psychiatr Clin North Am*. 2012;35(1):1-14.
- Massie MJ. Prevalence of depression in patients with cancer. *J Natl Cancer Inst Monogr*. 2004;32(2):57-71.
- Puccio F, Fuller-Tyszkiewicz M, Ong D, Krug I. A systematic review and meta-analysis on the longitudinal relationship between eating pathology and depression. *Int J Eat Disord*. 2016. doi:10.1002/eat.22506. [Epub ahead of print]
- Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. *Dialogues Clin Neurosci*. 2008;10(4):473-481.
- Shalev Y, Freedman S, Peri T, et al. Prospective study of posttraumatic stress disorder and depression following trauma. *Am J Psychiatry*. 1998;155(5):630-637.
- Centers for Disease Control and Prevention, National Center for Health Statistics. Depression and smoking in the U.S. household population aged 20 and over, 2005-2008. *NCHS Data Brief*. 2010;(34):1-8. www.cdc.gov/nchs/data/databriefs/db34.pdf. Accessed October 6, 2015.
- Katon W. Epidemiology and treatment of depression in patients with chronic medical illness. *Dialogues Clin Neurosci*. 2011;13(1):7-23.
- Centers for Disease Control and Prevention. Depression. www.cdc.gov/nchs/fastats/depression.htm. Accessed September 22, 2015.
- US Department of Health and Human Services. *Mental Health: Culture, Race, and Ethnicity*. Rockville, MD: US Department of Health and Human Services; 2001.
- Kroenke K, Spitzer RL, Williams JB. The patient health questionnaire-2: validity of a two-item depression screener. *Med Care*. 2003;41(11):1284-1292.
- Kroenke K, Spitzer RL. The PHQ-9: a new depression and severity measure. *Psychiatr Ann*. 2002;32(9):509-521.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, 5th ed (DSM-5)*. Arlington, VA: American Psychiatric Association Publishing; 2013.
- Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. *J Gen Intern Med*. 2009;24(7):783-788.
- Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. *Arch Intern Med*. 2010;170(13):1155-1160.
- Western Interstate Commission for Higher Education (WICHE) and Suicide Prevention Resource Center (SPRC). *Suicide Prevention Toolkit for Rural Primary Care. A Primer for Primary Care Providers*. Boulder, CO: Western Interstate Commission for Higher Education; 2009. www.sprc.org/sites/sprc.org/files/pctoolkit.pdf. Accessed March 7, 2016.
- Han B, Gfroerer J, McKeon R. Suicidal ideation among community-dwelling adults in the United States. *Am J Public Health*. 2014;104(3):488-497.
- Simon GE, Rutter CM, Peterson D, et al. Does response on the PHQ-9 Depression Questionnaire predict subsequent suicide attempt or suicide death? *Psychiatr Serv*. 2013;64(12):1195-1202.
- Intermountain Healthcare. *Management of Depression—2015 Update*. <https://intermountainhealthcare.org/ext/Dcmnt?ncid=51061767>. Accessed March 1, 2016.
- Intermountain Healthcare. *Suicide Prevention*. December 2014. <https://intermountainhealthcare.org/ext/Dcmnt?ncid=526742474>. Accessed March 23, 2016.
- Simmons LA, Wolever RQ, Bechard EM, Snyderman R. Patient engagement as a risk factor in personalized health care: a systematic review of the literature on chronic disease. *Genome Med*. 2014;26;6(2):16. doi:10.1186/gm533.
- Voinov B, Richie WD, Bailey RK. Depression and chronic diseases: it's time for a synergistic mental health and primary care approach. *Prim Care Companion CNS Disord*. 2013;15(2). doi:10.4088/PCC.12r01468.
- Bachman J, Swenson S, Reardon ME, Miller D. Patient self-management in the primary care treatment of depression. *Adm Policy Ment Health*. 2006;33(1):76-85.
- American Psychiatric Association. *Practice Guideline for the Treatment of Patients with Major Depressive Disorder*. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed December 15, 2015.
- Mura G, Moro MF, Patten SB, Carta MG. Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. *CNS Spectr*. 2014;19(6):496-508.
- US Department of Health and Human Services, Office of Disease Prevention and Health Promotion. *2008 Physical Activity Guidelines for Americans*. www.health.gov/paguidelines. Accessed April 5, 2016.
- Carek PJ, Laibstein SE, Carek SM. Exercise for the treatment of depression and anxiety. *Int J Psychiatry Med*. 2011;41(1):15-28.
- Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. *Cochrane Database Syst Rev*. 2013;9:CD004366.
- Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. *Psychosom Med*. 2007;69(7):587-596.
- Shedler J. The efficacy of psychodynamic psychotherapy. *Am Psychol*. 2010;65(2):98-109.
- Bell AC., D'Zurilla TJ. Problem-solving therapy for depression: a meta-analysis. *Clin Psychol Rev*. 2009;29(4):348-353.
- Bentley SM, Pagalilauan GL, Simpson SA. Major depression. *Med Clin North Am*. 2014;98(5):981-1005.
- Dupuy JM, Ostacher MJ, Huffman J, Perlis RH, Nierenberg AA. A critical review of pharmacotherapy for major depressive disorder. *Int J Neuropsychopharmacol*. 2011;14(10):1417-1431.
- Lin SY, Stevens MB. The symptom cluster-based approach to individualize patient-centered treatment for major depression. *J Am Board Fam Med*. 2014;27(1):151-159.
- Brintellix [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2014. <http://general.takedapharm.com/content/file.aspx?applicationcode=396066C6-E50F-4113-ABAD-54FE9525BF7E&filetypecode=BRINTELLIXPI&cacheRandomizer=7d4abb9d-1e2a-4cd1-bfb4-1faf5cdc9be1>. Accessed March 7, 2016.

(Continued on next page)



42-09 28th Street, Long Island City, NY 11101 (347) 396-2914

Bill de Blasio
Mayor

Mary T. Bassett, MD, MPH
Commissioner of Health and Mental Hygiene

Division of Mental Hygiene
Gary S. Belkin, MD, PhD, MPH, Executive Deputy Commissioner

Bureau of Mental Health
Myla Harrison, MD, MPH, Assistant Commissioner
Pablo Sadler, MD, MPH, Medical Director

Bureau of Systems Strengthening & Access
Monika Erős-Sarnyai, MD, MA, Best Practices Specialist
Aman Nakagawa, MS, LMSW,
Deputy Director, Health Integration Policy

Division of Epidemiology
R. Charon Gwynn, PhD, Deputy Commissioner

Provider Education Program
Ram Koppaka, MD, PhD, Director
Peggy Millstone, Director, Scientific Education Unit
Peter Ephross, Medical Editor
Rhoda Schlamm, Medical Editor

Consultant: Sonali Das, MPH, LCSW, CPH

Copyright ©2016 The New York City Department of Health and Mental Hygiene
E-mail *City Health Information* at: nycdohp@health.nyc.gov
New York City Department of Health and Mental Hygiene. Detecting and treating depression in adults.
City Health Information. 2016;35(1):1-12.



(Continued from previous page)

<p>47. Celexa [package insert]. St Louis, MO: Forest Pharmaceuticals, Inc.; 2014. http://pi.actavis.com/data_stream.asp?product_group=1906&p=pi&language=E. Accessed January 4, 2016.</p> <p>48. Cymbalta [package insert]. Indianapolis, IN: Lilly USA, LLC; 2015. http://pi.lilly.com/us/cymbalta-pi.pdf. Accessed January 4, 2016.</p> <p>49. Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2015. http://labeling.pfizer.com/ShowLabeling.aspx?id=100. Accessed January 5, 2016.</p> <p>50. Fetzima [package insert]. St Louis, MO: Forest Pharmaceuticals, Inc.; 2014. http://pi.actavis.com/data_stream.asp?product_group=1903&p=pi&language=E#page=1. Accessed January 4, 2016.</p> <p>51. Lexapro [package insert]. St Louis, MO: Forest Pharmaceuticals, Inc.; 2014. http://pi.actavis.com/data_stream.asp?product_group=1907&p=pi&language=E. Accessed January 4, 2016.</p> <p>52. Paxil CR [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020936s049lbl.pdf. Accessed January 5, 2016.</p> <p>53. Peveva [package insert]. Noven Pharmaceuticals, Inc.: Miami, FL; 2014. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c4d4603-190a-496fa40fbc09853b9820. Accessed March 7, 2016.</p> <p>54. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2014. http://labeling.pfizer.com/showlabeling.aspx?id=497. Accessed January 5, 2016.</p> <p>55. Prozac [package insert]. Indianapolis, IN: Lilly USA, LLC; 2014. http://pi.lilly.com/us/prozac.pdf. Accessed January 4, 2016.</p> <p>56. Remeron [package insert]. Whitehouse Station, NJ: Merck USA; 2012. http://www.merck.com/product/usa/pi_circulars/r/remeron/remeron_tablets_pi.pdf. Accessed January 4, 2016.</p> <p>57. Wellbutrin XL [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2014. http://www.wellbutrinxl.com/. Accessed January 4, 2016.</p> <p>58. Wellbutrin SR [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Wellbutrin_SR/pdf/WELLBUTRIN-SR-PI-MG.PDF. Accessed April 15, 2016.</p> <p>59. Viibryd [package insert]. Parsippany, NJ: Actavis, Inc.; 2015. http://pi.actavis.com/data_stream.asp?product_group=1905&p=pi&language=E. Accessed January 5, 2016.</p> <p>60. Zoloff [package insert]. New York, NY: Pfizer Inc; 2014. http://labeling.pfizer.com/ShowLabeling.aspx?id=517#page=1. Accessed January 5, 2016.</p>	<p>61. Hirsch M, Birnbaum RJ. Selective serotonin reuptake inhibitors: pharmacology, administration, and side effects. UpToDate. http://www.uptodate.com/contents/selective-serotonin-reuptake-inhibitors-pharmacology-administration-and-side-effects. Accessed February 26, 2016.</p> <p>62. Cameron C, Habert J, Anand L, Furtado M. Optimizing the management of depression: primary care experience. <i>Psychiatry Res</i>. 2014;220(Suppl 1):S45-S57.</p> <p>63. Community Preventive Services Task Force. Recommendations from the Community Preventive Services Task Force for use of collaborative care for the management of depressive disorders. <i>Am J Prev Med</i>. 2012;42(5):521-524.</p> <p>64. Archer J, Bower P, Gilbody S, et al. Collaborative care for depression and anxiety problems. <i>Cochrane Database Syst Rev</i>. 2012;10:CD006525.</p> <p>65. Interian A, Lewis-Fernandez R, Dixon L. Improving treatment engagement of underserved U.S. racial-ethnic groups: a review of recent interventions. <i>Psychiatr Serv</i>. 2013;64(3):212-222.</p> <p>66. Atlantis E, Fahey P, Foster J. Collaborative care for comorbid depression and diabetes: a systematic review and meta-analysis. <i>BMJ Open</i>. 2014;4(4):e004706. doi:10.1136/bmjopen-2013-004706.</p> <p>67. Huang Y, Wei X, Wu T, Chen R, Guo A. Collaborative care for patients with depression and diabetes mellitus: a systematic review and meta-analysis. <i>BMC Psychiatry</i>. 2013;13:260.</p> <p>68. Unutzer J, Harbin H, Schoenbaum M. Collaborative care model: An approach for integrating physical and mental health care in Medicaid health homes. Health Home Information Resource Center. May 2013. www.medicaid.gov/State-Resource-Center/Medicaid-State-Technical-Assistance/Health-Homes-Technical-Assistance/Downloads/HH-IRC-Collaborative-5-13.pdf. Accessed October 5, 2015.</p> <p>69. Ng RC, Hirata CK, Yeung W, Haller E, Finley PR. Pharmacologic treatment for postpartum depression: A systematic review. <i>Pharmacotherapy</i>. 2010;30(9):928-941.</p> <p>70. US Food and Drug Administration. Revisions to Medication Guide. Medication Guide: Antidepressant Medications, Depression and Other Serious Mental Illnesses, and Suicidal Thoughts and Actions. www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm100211.pdf. Accessed October 6, 2015.</p> <p>71. Birmaher B, Brent D; AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(11):1503-1526.</p>
---	--